Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study.
|Videos|September 17, 2016
Questions to Still be Answered in Myelofibrosis
Author(s)Zeev Estrov, MD
Zeev Estrov, MD, professor of medicine, MD Anderson Cancer Center, discusses questions that still need to be answered in the myelofibrosis field.
Advertisement
Newsletter
Stay up to date on practice-changing data in community practice.
SubscribeAdvertisement
Related to this article
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Breakthrough Status to Multi-Cancer Early Detection Blood Test
2
FDA Clears Phase 2 Trial of B7-H3 CAR T MT027 for Brain Metastases
3
Alpha-Emitting RYZ101 Meets Phase 3 PFS End Point in Advanced GEP-NETs
4
Epigenomic ctDNA Assay Predicts Recurrence in Resected Melanoma
5